Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the company's CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma (rrMM) and reported financial results for the second quarter ended June 30, 2023.
https://finance.yahoo.com/news/arcellx-announces-partial-clinical-hold-200000610.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.